Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/EMP2_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/EMP2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/EMP2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/EMP2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/EMP2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/EMP2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/EMP2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/EMP2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/EMP2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/EMP2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/EMP2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00015705 | Oral cavity | NEOLP | vasculogenesis | 18/2005 | 80/18723 | 1.70e-03 | 1.18e-02 | 18 |
GO:004353413 | Oral cavity | NEOLP | blood vessel endothelial cell migration | 32/2005 | 176/18723 | 1.93e-03 | 1.30e-02 | 32 |
GO:003367423 | Oral cavity | NEOLP | positive regulation of kinase activity | 70/2005 | 467/18723 | 2.33e-03 | 1.50e-02 | 70 |
GO:004470614 | Oral cavity | NEOLP | multi-multicellular organism process | 37/2005 | 220/18723 | 3.69e-03 | 2.15e-02 | 37 |
GO:003004810 | Oral cavity | NEOLP | actin filament-based movement | 24/2005 | 127/18723 | 4.02e-03 | 2.29e-02 | 24 |
GO:007170921 | Oral cavity | NEOLP | membrane assembly | 12/2005 | 50/18723 | 5.55e-03 | 2.95e-02 | 12 |
GO:000701518 | Prostate | BPH | actin filament organization | 147/3107 | 442/18723 | 3.36e-18 | 1.15e-15 | 147 |
GO:003158910 | Prostate | BPH | cell-substrate adhesion | 110/3107 | 363/18723 | 4.64e-11 | 2.96e-09 | 110 |
GO:007265916 | Prostate | BPH | protein localization to plasma membrane | 89/3107 | 284/18723 | 5.00e-10 | 2.56e-08 | 89 |
GO:001081017 | Prostate | BPH | regulation of cell-substrate adhesion | 74/3107 | 221/18723 | 5.40e-10 | 2.70e-08 | 74 |
GO:009013216 | Prostate | BPH | epithelium migration | 104/3107 | 360/18723 | 2.96e-09 | 1.15e-07 | 104 |
GO:009013016 | Prostate | BPH | tissue migration | 105/3107 | 365/18723 | 3.21e-09 | 1.24e-07 | 105 |
GO:001063116 | Prostate | BPH | epithelial cell migration | 103/3107 | 357/18723 | 3.80e-09 | 1.44e-07 | 103 |
GO:004578518 | Prostate | BPH | positive regulation of cell adhesion | 120/3107 | 437/18723 | 5.22e-09 | 1.90e-07 | 120 |
GO:000166717 | Prostate | BPH | ameboidal-type cell migration | 128/3107 | 475/18723 | 5.69e-09 | 2.05e-07 | 128 |
GO:000195210 | Prostate | BPH | regulation of cell-matrix adhesion | 48/3107 | 128/18723 | 9.98e-09 | 3.34e-07 | 48 |
GO:001063216 | Prostate | BPH | regulation of epithelial cell migration | 87/3107 | 292/18723 | 1.18e-08 | 3.87e-07 | 87 |
GO:199077810 | Prostate | BPH | protein localization to cell periphery | 95/3107 | 333/18723 | 2.78e-08 | 8.13e-07 | 95 |
GO:000716010 | Prostate | BPH | cell-matrix adhesion | 72/3107 | 233/18723 | 4.17e-08 | 1.16e-06 | 72 |
GO:003367416 | Prostate | BPH | positive regulation of kinase activity | 122/3107 | 467/18723 | 8.59e-08 | 2.14e-06 | 122 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EMP2 | insertion | In_Frame_Ins | novel | c.444_445insCTTGTAATCCCA | p.Val148_Ala149insLeuValIlePro | p.V148_A149insLVIP | P54851 | protein_coding | | | TCGA-A2-A0CM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | PD |
EMP2 | insertion | Frame_Shift_Ins | novel | c.204_205insGCAGCCGCGC | p.Ile69AlafsTer56 | p.I69Afs*56 | P54851 | protein_coding | | | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
EMP2 | insertion | Frame_Shift_Ins | novel | c.202_203insGGAGGAGGGAGAATTTGGAAAGGAGAAAT | p.Met68ArgfsTer11 | p.M68Rfs*11 | P54851 | protein_coding | | | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
EMP2 | SNV | Missense_Mutation | rs587777482 | c.28G>A | p.Ala10Thr | p.A10T | P54851 | protein_coding | tolerated(0.08) | benign(0.146) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
EMP2 | SNV | Missense_Mutation | rs370673124 | c.359N>A | p.Arg120His | p.R120H | P54851 | protein_coding | tolerated(0.34) | benign(0.027) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR |
EMP2 | SNV | Missense_Mutation | | c.176N>A | p.Ser59Tyr | p.S59Y | P54851 | protein_coding | deleterious(0.04) | possibly_damaging(0.837) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR |
EMP2 | SNV | Missense_Mutation | rs587777482 | c.28G>A | p.Ala10Thr | p.A10T | P54851 | protein_coding | tolerated(0.08) | benign(0.146) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
EMP2 | SNV | Missense_Mutation | rs587777482 | c.28G>A | p.Ala10Thr | p.A10T | P54851 | protein_coding | tolerated(0.08) | benign(0.146) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EMP2 | SNV | Missense_Mutation | | c.418N>A | p.Gly140Ser | p.G140S | P54851 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EMP2 | SNV | Missense_Mutation | rs562241873 | c.232N>A | p.Ala78Thr | p.A78T | P54851 | protein_coding | deleterious(0.01) | possibly_damaging(0.456) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |